Sign up for our Oncology Central weekly news round-up

Thermo-responsive fibrinogen nanogels: a viable thermo-responsive drug delivery agent for breast cancer therapy?


Breast cancer is reported to be the most frequent cancer type in women worldwide, with approximately 1.7 million newly diagnosed cases reported in 2012. During their lifetime, approximately 12% of women in the USA will develop invasive breast cancer, the second leading cause of cancer death of women in the USA [1]. In India, 1000,000 new cases of breast cancer are being reported every year [2]. Both local and systemic therapies are available for breast cancer now. Current treatment methods for breast cancer include invasive surgical procedures, radiotherapy, hormone therapy and chemotherapy. These therapies are less effective and recurrence is still a major problem in breast cancer patients. These therapies impart severe side effects and significant toxicity to normal cells [3]. A minimally invasive local delivery system capable of delivering one or a combination of drugs may overcome risks associated with surgery and also reduce the toxicity of anticancer drugs to normal cells/tissues.

Click here to view the full article